Osteoporosis and the long-term risk of peripheral artery disease: a population-based longitudinal follow-up study in Taiwan

2022 ◽  
Author(s):  
Yu-Shiuan Liang ◽  
Kuo-Cheng Yeh ◽  
Shin-Liang Pan
Keyword(s):  
Peripheral Artery Disease ◽  
Population Based ◽  
Peripheral Artery ◽  
Follow Up Study ◽  
Artery Disease

scholarly journals Long-term tracking of fasting blood glucose variability and peripheral artery disease in people without diabetes

2020 ◽  
Vol 8 (1) ◽  
pp. e000896
Author(s):  
Xiu-Ting Sun ◽  
Cheng Zeng ◽  
Shao-Zhao Zhang ◽  
Hui-Min Zhou ◽  
Xiang-Bin Zhong ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Lower Extremity ◽  
Peripheral Artery Disease ◽  
Cox Regression ◽  
Fasting Blood Glucose ◽  
Ankle Brachial Index ◽  
Peripheral Artery ◽  
Artery Disease

IntroductionLong-term changes of fasting blood glucose (FBG) in relation to lower-extremity peripheral artery disease (lower-extremity PAD) in people without diabetes has barely been reported. Our study aimed to investigate the association between FBG variability and the incidence of lower-extremity PAD in people without diabetes.Research design and methodsWe included 7699 participants without prior lower-extremity PAD and diabetes from the Atherosclerosis Risk in Communities study in the final analysis. At least two measurements of FBG were required during follow-up. Variability of FBG was identified using SD, coefficient of variation (CV), variability independent of the mean (VIM) and average real variability. Lower-extremity PAD was defined as an ankle brachial index <0.9, or hospitalization with a lower-extremity PAD diagnosis. Cox regression model was used to calculate HR for incidence of lower-extremity PAD and FBG variability.ResultsDuring a median follow-up of 19.5 years, 504 (6.5 %) lower-extremity PAD events were observed, 54.4% (n=274) were male, and 17.5% (n=88) were African-American. FBG variability was positively associated with incident lower-extremity PAD, with a linear relationship. HRs for CV and VIM were 1.015 (95% CI: 1.001 to 1.03; p=0.023), and 1.032 (95% CI: 1.004 to 1.06; p=0.022) for lower-extremity PAD, respectively. Participants in the lowest quartile of CV were at lower lower-extremity PAD risk compared with the highest ones (HR: 1.499, 95% CI: 1.16 to 1.938; p=0.002).ConclusionsHigher FBG variability was independently associated with increased prevalence of lower-extremity PAD in people without diabetes.Trial registration numberNCT00005131.

scholarly journals MP525PLAQUE SCORE AS A PREDICTOR OF PERIPHERAL ARTERY DISEASE EVENTS IN JAPANESE INCIDENT HEMODIALYSIS PATIENTS: AN OBSERVATIONAL, FOLLOW UP STUDY

2016 ◽  
Vol 31 (suppl_1) ◽  
pp. i515-i515
Author(s):  
Toshihide Hayashi ◽  
Nobuhiko Joki ◽  
Yuri Tanaka ◽  
Masaki Iwasaki ◽  
Shun Kubo ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Hemodialysis Patients ◽  
Peripheral Artery ◽  
Follow Up Study ◽  
Artery Disease

Adverse Prognosis of Peripheral Artery Disease Treatments Associated With Diabetes: A Comprehensive Meta-Analysis

Angiology ◽  
2021 ◽  
pp. 000331972110424
Author(s):  
Jingyang Luan ◽  
Jie Xu ◽  
Weiquan Zhong ◽  
Yan Zhou ◽  
Hao Liu ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Meta Analysis ◽  
Primary Patency ◽  
Secondary Patency ◽  
Peripheral Artery ◽  
Secondary Endpoints ◽  
Artery Disease ◽  
Long Term Mortality

Many studies have investigated the influence of diabetes mellitus (DM) on outcomes in patients with peripheral artery disease (PAD). We performed a meta-analysis of the outcomes of PAD treatments in DM patients compared with those without DM. Long-term mortality was the primary endpoint. Secondary endpoints were in-hospital/30-day mortality, primary/secondary patency, amputation, and limb salvage. Thirty-one studies reporting 58113 patients were eligible for enrollment. The mean follow-up duration ranged from 1 to 89 months. DM was significantly associated with long-term mortality (relative risk (RR) = 1.67; 95% confidence intervals (CI), 1.43–1.94; P < .001). DM was also associated with significantly lower primary patency (RR = 0.74; 95% CI, 0.58–0.95; P = .001) and secondary patency (RR = 0.80; 95% CI, 0.67–0.96; P = .009). DM is associated with worse outcomes and adverse prognosis of treatment in patients with PAD, and may therefore be a modifiable risk factor for poor prognosis in PAD patients.

scholarly journals Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease

Heart ◽  
2021 ◽  
pp. heartjnl-2020-318758
Author(s):  
Gilles R Dagenais ◽  
Leanne Dyal ◽  
Jacqueline J Bosch ◽  
Darryl P Leong ◽  
Victor Aboyans ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Low Dose ◽  
Cardiovascular Death ◽  
Stroke Rate ◽  
Early Stopping ◽  
Peripheral Artery ◽  
Once Daily ◽  
Registration Number ◽  
Artery Disease

ObjectiveIn patients with chronic coronary or peripheral artery disease enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies trial, randomised antithrombotic treatments were stopped after a median follow-up of 23 months because of benefits of the combination of rivaroxaban 2.5 mg two times per day and aspirin 100 mg once daily compared with aspirin 100 mg once daily. We assessed the effect of switching to non-study aspirin at the time of early stopping.MethodsIncident composite of myocardial infarction, stroke or cardiovascular death was estimated per 100 person-years (py) during randomised treatment (n=18 278) and after study treatment discontinuation to non-study aspirin (n=14 068).ResultsDuring randomised treatment, the combination compared with aspirin reduced the composite (2.2 vs 2.9/100 py, HR: 0.76, 95% CI 0.66 to 0.86), stroke (0.5 vs 0.8/100 py, HR: 0.58, 95% CI 0.44 to 0.76) and cardiovascular death (0.9 vs 1.2/100 py, HR: 0.78, 95% CI 0.64 to 0.96). During 1.02 years after early stopping, participants originally randomised to the combination compared with those randomised to aspirin had similar rates of the composite (2.1 vs 2.0/100 py, HR: 1.08, 95% CI 0.84 to 1.39) and cardiovascular death (1.0 vs 0.8/100 py, HR: 1.26, 95% CI 0.85 to 1.86) but higher stroke rate (0.7 vs 0.4/100 py, HR: 1.74, 95% CI 1.05 to 2.87) including a significant increase in ischaemic stroke during the first 6 months after switching to non-study aspirin.ConclusionDiscontinuing study rivaroxaban and aspirin to non-study aspirin was associated with the loss of cardiovascular benefits and a stroke excess.Trial registration numberNCT01776424.

Sign in / Sign up

Export Citation Format

Share Document